Gynecologic Oncology practice @MassGenNews. Researching how real-world cancer care affects real-world patients. He/his/him/himself
Joined March 2013
- Tweets 948
- Following 1,169
- Followers 1,227
- Likes 2,030
107 Photos and videos
5 Aug 2025
Our latest lead by Dr. Katy Abel. More evidence that underutilization of NACT is associated with worse post-operative outcomes, without any hint of long-term benefit, even in high-volume centers.
25 Jul 2025
For patients with advanced-stage ovarian cancer, higher utilization of neoadjuvant chemotherapy at high-volume centers was associated with the lowest 90-day surgical mortality and longest 60-month survival. ja.ma/415zwCx
1
1
2
355
Alex Melamed retweeted
24 Jun 2025
Our JAMA Oncology study is now featured in the @IJGConline podcast! Thank you for highlighting our work.
Grateful to work with such an amazing team! @dviverosc @headofmelon @NiteckiRoni @RParejaGineOnco @RauhHainMD
23 Jun 2025
🎙️ New #IJGCConversations Episode!
🚨 Radiation alone vs. Chemoradiation in Intermediate Risk #CervicalCancer with @nagustiga and @dviverosc
🎧 Tune in now and stay ahead in #GynOnc!
🔗 bit.ly/43Wmg5b
@pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4 @HelenaObermair @sofiabigardiGMD @marina_rosanu @ChakraRim @FilippoCapom @mcgouveia_ @MDAndersonnews
7
25
1,293
Alex Melamed retweeted
10 Jan 2025
Our 15-year cohort study explores trends in surgical de-escalation in gynecologic oncology. These findings are transforming patient care but raise important questions about the preparation of fellows in surgical training.
@headofmelon @dviverosc @RauhHainMD @NiteckiRoni
8 Jan 2025
Gynecologic oncology is moving towards less invasive surgical methods and decreased surgery overall, which likely benefits patients but also raises challenges for surgical training and the equitable access. ja.ma/3DNOWmf
7
38
2,266
23 Nov 2024
LANCE trial lead-in pilot shows the feasibility of a phase III study to evaluate the efficacy of MIS for interval cytoreduction in ovarian cancer. @RauhHainMD @annafagottimd @RParejaGineOnco @pedroramirezMD @abedsinno
21 Nov 2024
LANCE RCT: A minimally invasive surgery for advanced ovarian cancer after neoadjuvant chemotherapy is feasible and may reduce postoperative complications compared to laparotomy. ja.ma/4eBRbpz
3
12
49
4,671
Alex Melamed retweeted
19 Nov 2024
#cancer during #pregnancy is associated with severe maternal and neonatal morbidity. Proud of the entire team for this important manuscript!
authors.elsevier.com/c/1k7m2…
@RauhHainMD @headofmelon @markaclapp @abigailflynt @dviverosc @nagustiga @MDAndersonNews @AJOG_thegray
1
7
18
1,103
14 Nov 2024
1
27
908
7 Nov 2024
Cool picture of a adenosarcoma assocaited uterine inversion which we treated laparoscopically. Nice work by Baran Vardar and @AlexBercowMD getting these pictures into the literature.
pubs.rsna.org/doi/10.1148/ry…
4
543
2 Nov 2024
Josseli Barnica is the victim of a totalitarian state imposing its ideology on women’s bodies. America we are better than this.
3
3
959
17 Oct 2024
NACT and interval cytoreductive surgery edges out primary cytoreductive surgery as the most frequent treatment for advanced-stage ovarian cancer in the US. 11 years after Vergote et al. It really does take a decade.
17 Oct 2024
Since 2021, neoadjuvant chemotherapy followed by interval cytoreductive surgery has become the most prevalent approach of upfront treatment for patients with advanced epithelial ovarian cancer in the US. ja.ma/4dNCjEa
1
13
742
Alex Melamed retweeted
17 Oct 2024
Since 2021, neoadjuvant chemotherapy followed by interval cytoreductive surgery has become the most prevalent approach of upfront treatment for patients with advanced epithelial ovarian cancer in the US. ja.ma/4dNCjEa
1
3
1,534
29 Aug 2024
Thanks @IJGConline and @pedroramirezMD for this great honor.
21 Aug 2024
📣 Great news!!!
Dr. Alexander Melamed joins the #IJGC #AssociateEditors team 🔥 🔥
Welcome Alex!🤩
@pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4
2
32
1,561
16 Jun 2023
A new paper by super intern Katy Abel looks at the use and efficacy of primary site surgery in metastatic cancer. There is a lot of heterogeneity across cancer sites, raising essential questions about how, and if, we know when surgery is helpful
onlinelibrary.wiley.com/doi/…
6
454
16 Jun 2023
A new paper by Jason Silberman @JSilby3: who is on the market for the gyn onc fellowship spot!
tinyurl.com/2pzjm748
cytotoxic NACT has increased for stage III&IV low-grade serous ovarian cancer in last 15y w/o evidence that this approach is effective in this cancer type
1
3
11
2,607
4 Jan 2023
Nice study from Vrede et al:
The molecular subtype may not be prognostically important for low-grade endometrioid endometrial cancer
Relevance of Molecular Profiling in Patients With Low-Grade Endometrial Cancer ja.ma/3jNizKm via @JAMANetworkOpen part of @JAMANetwork
5
13
1,027
Alex Melamed retweeted
7 Dec 2022
Our latest study in @JAMASurgery revealed that spending for cancer surgery decreased significantly among Medicare beneficiaries. Read the full text: jamanetwork.com/journals/jam… @headofmelon @NancyKeatingMD @anaeze_offodile
3
22
Alex Melamed retweeted
26 Nov 2022
If you last checked in on AI image makers a month ago & thought “that is a fun toy, but is far from useful…” Well, in just the last week or so two of the major AI systems updated.
You can now generate a solid image in one try. For example, “otter on a plane using wifi” 1st try:
276
2,029
17,661
22 Nov 2022
The dramatic difference between leg room one gets in economy compared to economy plus seems like an ominous symptom of declining solidarity in US society.
But also: I’m never flying regular economy again.
4
19 Oct 2022
When you ask the intern for the patient’s oncologic history on rounds:
3
1
18